Atavistik Bio uses its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform to discover and develop precision allosteric small‑molecule therapeutics by identifying cryptic allosteric pockets with metabolite‑guided and AI‑enabled methods. The integrated computational‑experimental workflow accelerates hit identification and lead optimization for high‑unmet‑need targets in oncology and rare diseases, enabling partners to drug previously intractable proteins with improved selectivity and tolerability.
Funding
$40M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional small‑molecule drug discovery often targets the active site of proteins, leaving roughly 90% of disease‑relevant proteins undruggable because suitable binding pockets are not apparent. Identifying functional allosteric sites that can be modulated by small molecules is a major bottleneck, limiting the development of selective and potent therapies for high‑unmet‑need diseases such as rare genetic disorders and certain cancers.
Solution
Atavistik Bio addresses this gap with its proprietary Atavistik Metabolite‑Protein Screening (AMPS) platform, which uses metabolites as molecular baits to reveal cryptic allosteric pockets across diverse protein classes. The platform combines computational modeling, AI‑enabled structure‑based design, and experimental validation to rapidly translate identified pockets into precision allosteric small‑molecule candidates. By focusing on natural protein regulators, the approach accelerates discovery of highly selective modulators that can differentiate mutant from wild‑type proteins, improving efficacy and tolerability. The integrated workflow enables fast iteration from pocket identification to lead optimization, supporting internal programs in oncology and rare diseases and providing a foundation for partnership‑driven expansion into additional therapeutic areas.
Target Audience
Primary customers are pharmaceutical and biotech companies seeking to drug previously intractable targets, particularly in precision oncology and rare disease programs, as well as research partners interested in leveraging allosteric discovery technology.
Features
- Metabolite‑guided screening that pinpoints functional allosteric sites not detectable by conventional methods
- AI‑powered structure‑based drug design engine for rapid generation of selective small‑molecule modulators
- Integrated computational‑experimental pipeline that streamlines pocket validation, hit identification, and lead optimization
- Capability to develop mutant‑selective inhibitors (e.g., JAK2 V617F, AKT1 E17K) that spare wild‑type activity
- Versatile platform applicable to a broad range of protein targets, enabling expansion beyond oncology and rare diseases